Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
about
AfliberceptProtocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) ..Treatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewClinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinomaRamucirumab in metastatic colorectal cancer: evidence to date and place in therapyTumor refractoriness to anti-VEGF therapyAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerMolecular testing to optimize therapeutic decision making in advanced colorectal cancerProfile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectivesAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraEvidence-based medical oncology and interventional radiology paradigms for liver-dominant colorectal cancer metastases.Pharmacologic resistance in colorectal cancer: a reviewProfile of bevacizumab and its potential in the treatment of cervical cancerTherapeutic strategy in unresectable metastatic colorectal cancer: an updated reviewEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsAnti-angiogenic agents in metastatic colorectal cancerManagement of colorectal cancerMolecularly targeted drugs for metastatic colorectal cancerValue of bevacizumab in treatment of colorectal cancer: A meta-analysisAnti-angiogenesis in prostate cancer: knocked down but not outThe role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trialsTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyThe place of targeted agents in the treatment of elderly patients with metastatic colorectal cancerReview of systemic therapies for locally advanced and metastatic rectal cancerManagement of locally advanced and metastatic colon cancer in elderly patientsHow to select the optimal treatment for first line metastatic colorectal cancerRegorafenib in metastatic colorectal cancer.Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerRole of targeted therapy in metastatic colorectal cancerRAS and BRAF in metastatic colorectal cancer managementPharmacotherapy for recurrent ovarian cancer: current status and future perspectivesSecond-line systemic therapy for metastatic colorectal cancer.Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer.Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised coThree-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
P2860
Q24600199-9BDA31EA-CB1E-48B0-AFB9-D1F862A302E4Q24658529-4E806002-C402-43F3-AE85-F760AE43A868Q26738801-F78C9639-B776-41EF-88A5-EBAE9C6AB5DDQ26740067-CBE2E383-B5E9-489E-808E-90D8766B85FAQ26741530-794B10F5-C1DD-456F-AB21-0EBCA4933B7BQ26745418-A046CC51-18D5-4BB0-B86C-E36FE8CE036AQ26747678-3DD424D4-6BE3-4E5C-92F3-D589C630F1E4Q26748924-3CD197F4-8AD3-41D1-85A8-5433C5A70587Q26749012-2D99EAC0-792C-4BE5-8592-19629BEE70CDQ26751280-D19C6BBF-DB89-41B5-9A0F-753EF8FA63CCQ26751344-3B670958-6C9C-48C1-B784-0D4C69343965Q26752747-4CE821F5-9746-49FA-B7C3-7932DD51E231Q26769850-F8A5BDCB-162E-4FA6-83DB-3182C97BBEAFQ26774168-83742438-908E-4038-B095-0467EC4B3731Q26775522-FC4E6E69-044D-417E-86AC-C3C1D4C8E7A9Q26777704-CF2A0195-3568-42A4-9E06-028737F1C40EQ26786618-172C03B9-C98D-4900-AFC7-FE50D07B8C69Q26801911-2E2CA89D-3780-404C-801A-1020D524C92EQ26823550-612963D0-EE0B-495A-9D70-597CCEF42D4AQ26828735-43F18925-A504-4C1E-A668-AF3A45209A89Q26849789-C03F6D96-318A-4C60-AFF0-28823B7D61AEQ26851183-687CF243-3DE4-496A-AF5F-2B5BC57F2C1EQ26858892-391D9EDA-E70E-4B86-A63C-695120155A8AQ26993238-38C6D31A-EF5C-45AF-A89B-36775577FFE4Q27011366-E3045F34-6B5B-473E-85A1-9BB227B9586AQ27021105-879088D7-BB5E-407E-9722-34032E91F30BQ27026129-AD528C5E-6CE9-4755-9129-E0360F104C76Q27026516-8FF9306C-3C13-4981-A8E7-3C3AC80AB894Q27852864-72C300E4-4806-4532-89DB-499DFF04FCB5Q27853074-8A8AA716-93EF-48BC-9A51-E8FB45603338Q28068654-151C431C-ABE8-4D11-BDD7-31F8C3818291Q28068817-C1D2C1F0-EBB0-47BA-B93B-18174E2472EAQ28074175-E6533468-FCC0-42A5-A565-3AD28E5F5CA4Q28083801-B8D6C298-FDB9-43BC-B0CB-8B09315626B9Q30238760-1CD51849-72C1-42F9-90A6-BC03F583ED6FQ30244769-6E45804A-590D-4460-A8AF-024EB341FD36Q30248296-5AFCFC93-527E-4962-B64E-94799A4A6442Q30249335-77D75067-36EB-4F7E-AC0C-9F61AA567A31Q30316930-14832FED-F3CA-4A7E-B0E3-C621AEA53556Q30384642-914BECAD-D218-4546-97C2-3525CCCA10C7
P2860
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Continuation of bevacizumab af ...... ): a randomised phase 3 trial.
@ast
Continuation of bevacizumab af ...... ): a randomised phase 3 trial.
@en
Continuation of bevacizumab after first progression in metastatic colorectal cancer
@nl
type
label
Continuation of bevacizumab af ...... ): a randomised phase 3 trial.
@ast
Continuation of bevacizumab af ...... ): a randomised phase 3 trial.
@en
Continuation of bevacizumab after first progression in metastatic colorectal cancer
@nl
prefLabel
Continuation of bevacizumab af ...... ): a randomised phase 3 trial.
@ast
Continuation of bevacizumab af ...... ): a randomised phase 3 trial.
@en
Continuation of bevacizumab after first progression in metastatic colorectal cancer
@nl
P2093
P50
P921
P1433
P1476
Continuation of bevacizumab af ...... ): a randomised phase 3 trial.
@en
P2093
Belguendouz Bendahmane
Christoph Schlichting
Christophe Borg
Claus-Christoph Steffens
Irmarie Reyes-Rivera
Jaafar Bennouna
Javier Sastre
Jose Maria Viéitez
ML18147 Study Investigators
Olivier Bouché
P356
10.1016/S1470-2045(12)70477-1
P577
2012-11-16T00:00:00Z